电 ?? 疗法通过调节水利素来改善刺激性肠综合征的老鼠的肠壁功能
Xueling Kang1, Honglin Zhang1, Xiaying Li2
1School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, 100029, China.
Digestive diseases and sciences
|February 29, 2024
概括
电针 (EA) 通过调节水合素 (AQPs) 和紧结 (TJs) 来改善腹 (IBS-D) 的刺激性肠综合征. 此外,EA还可以恢复肠道屏障功能,并平衡IBS-D大鼠的肠道微生物群.
科学领域:
- 胃肠病学 胃肠病学
- 综合医学是一个整体医学.
- 微生物学 微生物学
背景情况:
- 肠粘膜屏障功能障碍是刺激性肠综合征与腹 (IBS-D) 发病的关键.
- 电针 (EA) 在IBS-D.中被探索其治疗机制.
- 专注于EA对水素 (AQPs),紧接点 (TJs),NF-κB通路和肠道微生物群的影响.
研究的目的:
- 为了研究EA在IBS-D大鼠肠道粘膜屏障上的治疗机制.
- 评估EA对AQPs,TJs,NF-κB信号传递和肠道微生物群组成的影响.
主要方法:
- IBS-D大鼠模型由乙酸透水和慢性制压力诱导.
- 通过行为评分,便含水量和肠道运输来评估EA的疗效.
- 使用16S rRNA测序对AQPs,TJs,炎症标志物和肠道微生物群的分析.
主要成果:
- EA降低了肠道敏感性,改善了运动性和炎症细胞透.
- EA显著改善了肠道炎症,并调节了肠道菌群环境.
- EA抑制了NF-κB通路,减少了炎症因素 (IL-1β,TNF-α),并调节了AQP和TJ表达.
结论:
- EA抑制NF-κB通路并调节AQP和TJ蛋白质,恢复IBS-D患者的水代谢和肠道透性.
- 治疗EA可以重新平衡肠道菌群,从而恢复IBS-D患者的肠道粘膜功能.
- 通过解决屏障功能障碍和微生物失衡,EA显示出作为IBS-D治疗策略的潜力.
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
169
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
169
Irritable Bowel Syndrome I: Introduction
273
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
273
Drugs for Treatment of Constipation-Predominant IBS
163
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
163
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
212
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
212


